NSE IPCALAB · BSE 524494 · Biotechnology & Drugs · NIFTY 500

IPCA Laboratories Share Price

Market closed · updated 25 Sep, 4:40 PM IST

₹1,994.70 ▲ +₹30.64 · 1.56% NSE · as of 24 Sep 2026, 8:34 AM · BSE ₹1,993.80

Today's range

₹1,966.65Low₹2,005.55High

52-week range

₹1,252.95Low · 24 Oct 2025₹2,039.30High · 18 Sep 2026

IPCA Laboratories Overview

Where the price stands, how it has moved and how it sits against its averages.

IPCA Laboratories shares last traded at ₹1,994.70 on the NSE, up 1.56% on the day. That is 2.2% below the 52-week high of ₹2,039.30 and 59.2% above the 52-week low of ₹1,252.95. The stock trades at 32.95× earnings, below the sector average of 36.50. Its market value is ₹50,568 Cr.

Price returns

1 Day▲ +1.56%

5 Days▲ +0.61%

This month▼ −0.62%

3 Months▲ +21.06%

6 Months▲ +25.01%

This year▲ +38.32%

1 Year▲ +40.67%

Against the market: 1 Month ▲ +4.08% · 3 Months ▲ +24.56% · 6 Months ▲ +25.75% · This year ▲ +57.53% · 1 Year ▲ +54.34%

Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.

Moving averages — price is above 6 of 6

Today's price₹1,994.70
5-day average₹1,986.24 ▲ price 0.4% above
10-day average₹1,973.38 ▲ price 1.1% above
20-day average₹1,964.28 ▲ price 1.5% above
50-day average₹1,865.88 ▲ price 6.9% above
100-day average₹1,739.03 ▲ price 14.7% above
300-day average₹1,607.03 ▲ price 24.1% above

Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.

IPCA Laboratories Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore

9,646

Net profit₹ crore · losses below zero

1,141

Year by year

Fiscal year	Revenue	Growth	Net profit	Net margin	EPS	Dividend
FY 2026	₹9,646 Cr	▲ +7.9%	₹1,141 Cr	11.8%	₹44.98	₹6.00
FY 2025	₹8,940 Cr	▲ +16.0%	₹738 Cr	8.3%	₹29.08	₹4.00
FY 2024	₹7,705 Cr	▲ +23.4%	₹547 Cr	7.1%	₹21.57	₹4.00
FY 2023	₹6,244 Cr	▲ +7.1%	₹471 Cr	7.5%	₹18.58	₹4.00
FY 2022	₹5,830 Cr	▲ +7.6%	₹884 Cr	15.2%	₹34.85	₹4.00
FY 2021	₹5,420 Cr	▲ +16.6%	₹1,140 Cr	21.0%	₹45.01	₹4.00
FY 2020	₹4,649 Cr	—	₹606 Cr	13.0%	₹23.98	₹2.50

Revenue₹ crore

2,788

Net profit₹ crore · losses below zero

402

Quarter by quarter

Quarter	Revenue	vs prev. qtr	Net profit	Net margin	EPS
Q1 FY27	₹2,788 Cr	▲ +16.7%	₹402 Cr	14.4%	₹15.84
Q4 FY26	₹2,388 Cr	▼ −0.2%	₹299 Cr	12.5%	₹11.79
Q3 FY26	₹2,393 Cr	▼ −6.4%	₹326 Cr	13.6%	₹12.86
Q2 FY26	₹2,557 Cr	▲ +10.7%	₹283 Cr	11.1%	₹11.14
Q1 FY26	₹2,309 Cr	▲ +2.8%	₹233 Cr	10.1%	₹9.19
Q4 FY25	₹2,247 Cr	▲ +0.1%	₹68 Cr	3.0%	₹2.67
Q3 FY25	₹2,245 Cr	▼ −4.7%	₹248 Cr	11.1%	₹9.78
Q2 FY25	₹2,355 Cr	—	₹229 Cr	9.7%	₹9.05

Balance sheet — FY26

Owes (liabilities)Shareholders' equity

35%

65%

Total assets₹12,370 Cr
Total liabilities₹4,306 Cr
Shareholders' equity₹8,064 Cr
Total debt₹809 Cr
Cash & investments₹1,191 Cr
Current ratio2.76×
Revenue growth, 5 yr12.22% a year
EPS growth, 5 yr−0.01% a year
Operating margin (TTM)16.78%
Net margin (TTM)13.63%

Cash flow — FY26

Operating activities

▲ ₹1,142 Cr

Investing activities

▼ −₹247 Cr

Financing activities

▼ −₹754 Cr

Free cash flow

▲ ₹486 Cr

Net change in cash

▲ ₹142 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Total revenue	4,648.71	5,419.99	5,829.79	6,244.32	7,705.04	8,939.59	9,646.33
Cost of revenue	1,939.74	2,008.86	2,348.09	2,691.25	3,059.76	3,281.73	3,338.61
Gross profit	2,708.97	3,411.13	3,481.70	3,553.07	4,645.28	5,657.86	6,307.72
Operating expenses	3,935.39	4,122.44	4,771.44	5,544.76	6,949.47	7,847.31	8,095.81
Operating income	713.32	1,297.55	1,058.35	699.56	755.57	1,092.28	1,550.52
Depreciation	210.50	209.17	232.42	261.56	357.24	397.82	418.12
Profit before tax	738.89	1,381.28	1,114.56	745.29	842.67	1,131.14	1,572.52
Tax	135.33	240.14	224.77	253.36	313.46	343.61	381.15
Net profit	606.32	1,140.01	884.08	471.32	547.35	737.68	1,141.12
EPS (₹)	23.98	45.01	34.85	18.58	21.57	29.08	44.98
Dividend per share (₹)	2.50	4.00	4.00	4.00	4.00	4.00	6.00

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Total assets	5,259.83	6,068.36	7,623.53	8,626.43	11,101.28	11,760.55	12,370.19
Current assets	2,855.71	3,436.96	4,457.17	5,189.27	5,538.90	5,967.04	6,373.61
Cash & short-term investments	418.23	768.81	1,370.05	2,180.09	845.35	1,105.05	1,190.52
Inventory	1,338.42	1,610.55	1,889.73	1,773.21	2,511.95	2,599.41	2,775.08
Property, plant & equipment	1,993.25	2,146.45	2,502.59	2,694.58	4,663.24	4,685.34	5,202.40
Total liabilities	1,632.35	1,366.71	2,158.69	2,784.41	4,769.09	4,812.10	4,306.38
Current liabilities	1,326.42	1,160.54	1,465.88	1,805.82	2,355.64	2,386.22	2,306.93
Total debt	500.72	265.39	807.22	1,481.27	1,438.36	1,362.74	808.76
Total equity	3,627.48	4,701.65	5,464.84	5,842.02	6,332.19	6,948.45	8,063.81

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
From operations	564.58	1,090.13	860.16	805.81	1,021.15	1,321.32	1,141.97
From investing	−509.65	−520.69	−855.05	−725.00	−1,291.79	−869.50	−246.77
From financing	−130.46	−305.82	426.81	507.24	−552.55	−282.98	−753.53
Capital expenditure	−306.28	−361.55	−478.95	−494.47	−411.29	−775.57	−655.95
Dividends paid	−121.66	−101.53	−101.45	−101.48	−50.74	−101.48	−52.41
Net change in cash	−75.53	263.62	431.92	588.05	−823.19	168.84	141.67

What Analysts Say

16 analysts

Recommendations from 16 analysts who cover IPCA Laboratories.

Buy average rating 2.00 on a 1–5 scale

Strong buyBuyHoldSellStrong sell

▲ 12 bullish (75.0%) · 2 hold (12.5%) · ▼ 2 bearish (12.5%)

Votes

Strong Buy

7 (44%)

Buy

5 (31%)

Hold

2 (13%)

Sell

1 (6%)

Strong Sell

1 (6%)

How the votes changed

Rating	3M ago	2M ago	1M ago	1W ago	Now	3-month change
Strong Buy	7	7	7	7	7	—
Buy	5	5	5	5	5	—
Hold	2	2	2	2	2	—
Sell	0	0	0	1	1	▲ +1
Strong Sell	0	0	1	1	1	▲ +1

Analyst ratings are opinions, not a guarantee of returns.

IPCA Laboratories vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

Company	Price	Change	Market cap	P/E	P/B	ROE (5 yr)	Net margin	Div. yield	Rating
IPCA Laboratories	₹1,994.70	▲ +1.56%	₹50,568 Cr	32.95	6.17	12.21%	13.63%	0.31%	This stock
Sun Pharmaceutical Industries	₹1,850.30	▼ −0.79%	₹4,43,938 Cr	38.40	5.55	14.22%	19.12%	0.83%	Moderately Bearish
Divi's Laboratories	₹9,620.50	▲ +0.25%	₹2,55,394 Cr	73.32	11.48	16.87%	24.32%	0.41%	Bullish
Torrent Pharmaceuticals	₹4,930.10	▼ −1.00%	₹1,87,518 Cr	72.73	19.22	23.00%	15.29%	0.80%	Bullish
Cipla	₹1,395.40	▲ +1.12%	₹1,12,729 Cr	27.57	3.33	14.47%	13.74%	0.92%	Neutral
Zydus Lifesciences	₹1,175.05	▲ +0.47%	₹1,17,212 Cr	21.19	4.24	17.90%	18.51%	0.09%	Bullish

Rating = the data provider's overall technical view of each peer. Company names link to their own pages.

Shareholding Pattern

Who owns IPCA Laboratories shares, quarter by quarter (latest on top).

PromoterFIIMFOther

Jun '26

44.7%

10.7%

31.2%

13.4%

Mar '26

Dec '25

Sep '25

Holder	Sep '25	Dec '25	Mar '26	Jun '26	Change
Promoter	44.72%	44.72%	44.72%	44.72%	0.00 pts
FII	10.42%	10.62%	10.63%	10.72%	▲ +0.09 pts
MF	30.04%	30.52%	31.24%	31.15%	▼ −0.09 pts
Other	14.82%	14.14%	13.41%	13.41%	0.00 pts

IPCA Laboratories Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

IPCA LaboratoriesBenchmarkComfortable → stretched

Valuation Is the price reasonable?

P/E (TTM)Price ÷ yearly earnings per share

32.95

▼ 10% below the sector average of 36.50

P/E, 12-month rangeLow 31.05 · high 58.95

Today's P/E sits 7% of the way from its low to its high

P/BPrice ÷ book value per share

6.17

P/SPrice ÷ sales per share

4.92

P/CFPrice ÷ cash flow per share

27.53

PEGP/E ÷ earnings growth (≈1 is fair)

1.11

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods

71.08%

▲ above its 5-yr average of 61.63%

Operating marginKept after running costs

16.78%

▲ above its 5-yr average of 13.44%

Pre-tax marginKept before tax

17.92%

▲ above its 5-yr average of 14.09%

Net marginKept as profit

13.63%

▲ above its 5-yr average of 10.14%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money

15.20%

▲ above its 5-yr average of 12.21%

Return on assetsProfit on everything it owns

9.87%

▲ above its 5-yr average of 8.05%

Return on investmentProfit on long-term capital

14.41%

▲ above its 5-yr average of 11.16%

Growth Is the business getting bigger?

Revenue — last 12 months

+10.6%

▲ growing

Revenue — 3 yr, a year

+15.6%

▲ growing

Revenue — 5 yr, a year

+12.2%

▲ growing

EPS — last 12 months

+68.2%

▲ growing (off the scale)

EPS — 3 yr, a year

+34.3%

▲ growing (off the scale)

EPS — 5 yr, a year

−0.0%

▼ shrinking

Dividend — 3 yr, a year

+14.5%

▲ growing

Book value — 5 yr, a year

+11.4%

▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money

0.10×

✓ Low debt

Current ratioShort-term assets for every ₹1 due within a year

2.76×

✓ Comfortable

Quick ratioLike the current ratio, without inventory

1.56×

✓ Comfortable

Interest coverOperating profit ÷ interest to pay

26.01×

✓ Strong

Payout ratioShare of profit paid as dividend

13.34%

• Keeps most

Per share What each share stands for

EPS (TTM)

₹51.63

Book value

₹317.85

Cash flow

₹71.29

Dividend

₹6.00

Revenue

₹399.12

The share price is 6.28× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 111 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year43.63

Current Dividend Yield - Common Stock Primary Issue, LTM0.31

Price to Book - most recent fiscal year6.17

P/E Basic excluding extraordinary items - TTM32.95

P/E including extraordinary items - TTM38.01

P/E excluding extraordinary items low, trailing 12 months31.05

Price to Tangible Book - most fiscal year6.33

Dividend Yield - 5 Year Average0.35

Price to sales - most recent fiscal year5.16

Dividend Yield - indicated annual dividend divided by closing price0.31

Price to Cash Flow per share - trailing 12 month27.53

Peg Ratio1.11

Price to Free Cash Flow per Share - most recent fiscal year114.83

P/E Normalized, most recent fiscal year41.92

P/E excluding extraordinary items high, trailing 12 months58.95

P/E excluding extraordinary items, most recent fiscal year quarter38.01

Price to sales - trailing 12 month4.92

Net Debt, LFY−3,817.60

Per share

Dividend Per Share - 5 year average4.40

Cash Flow per share - trailing 12 month71.29

Cash Flow per share - most recent fiscal year63.44

EPS including extraordinary items - trailing 12 month51.63

EPS including extraordinary items - most recent fiscal year44.98

EBITD per share - trailing 12 month87.97

Revenue/share - trailing 12 month399.12

EPS excluding extraordinary items - trailing 12 month51.63

EPS Basic excluding extraordinary items - most recent fiscal year44.98

EPS Basic excluding extraordinary items - trailing 12 month51.63

Book value per share - most recent fiscal year317.84

Dividend per share - most recent fiscal year6.00

Revenue/share - most recent fiscal year380.22

EPS Normalized - most recent fiscal year46.82

Book value (tangible) per share - most recent fiscal year310.06

Dividends per share - trailing 12 month6.00

EPS excluding extraordinary items - most recent fiscal year44.98

Cash per share - most recent fiscal year46.93

Margins

Operating margin - trailing 12 month16.78

Gross Margin - 5 year average61.63

Operating margin - 1st historical fiscal year16.07

Operating Margin - 5 year average13.44

Net Profit Margin % - 1st historical fiscal year12.35

Gross Margin - 1st historical fiscal year65.39

Net Profit Margin % - trailing 12 month13.63

Net Profit Margin - 5 year average10.14

Pretax Margin - 5 year average14.09

Pretax margin - 1st historical fiscal year16.30

Pretax margin - trailing 12 month17.92

Free Operating Cash Flow/Revenue, 5 Year Average5.02

Gross Margin - trailing 12 month71.08

Growth

EPS Change %, TTM over TTM68.20

Revenue growth rate, 5 year12.22

EPS growth rate, 5 year−0.01

Revenue Change % - most recent quarter 1 year ago20.76

Growth rate% - dividend, 3 year14.47

Growth rate% - EPS, 3 year34.28

Revenue/share (5 yr growth)12.18

Free Operating Cash Flow, 5 Year CAGR−7.11

Tangible Book Value, Total Equity, 5 Year CAGR11.62

Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR10.21

Capital Spending growth rate, 5 year12.65

Revenue Change %, TTM over TTM10.59

Growth rate% - Revenue, 3 year15.60

Book value per share growth rate, 5 year11.39

EPS Change % - most recent quarter 1 year ago72.36

Net Profit Margin growth rate, 5 year−10.12

Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR6.02

Total Debt, 5 Year CAGR24.96

Financial strength

Free Cash Flow - most recent fiscal year4,336.10

LT debt/equity - most recent fiscal year0.02

Quick ratio - most recent fiscal year1.56

Payout ratio - trailing 12 month11.62

Current ratio - most recent fiscal year2.76

Current EV/Free Cash Flow, LFY56.45

Total debt/total equity - most recent fiscal year0.10

Net Interest coverage - trailing 12 month26.01

Payout ratio - most recent fiscal year13.34

Returns & efficiency

Return on average equity - 5 year average12.21

Net Income/employee - trailing 12 month8,01,719.90

Revenue/employee - most recent fiscal year56,76,315.00

Return on investment - most recent fiscal year14.41

Return on average assets - most recent fiscal year9.87

Receivables turnover - most recent fiscal year4.94

Inventory turnover - most recent fiscal year1.24

Revenue/employee - trailing 12 month58,83,545.00

Return on average assets - 5 year average8.05

Net Income/employee - most recent fiscal year7,01,053.30

Asset turnover - most recent fiscal year0.80

Return on average equity - most recent fiscal year15.20

Return on investment - 5 year average11.16

Price & volume

Market Cap50,568.28

52 week Low Date24 Oct 2025

Price - 1 Day % Change−1.50

Relative (S&P500) price percent change - 13 week24.56

Avg trading volume last 10 days0.27

Price - 13 week price percent change21.06

Price - 52 week price percent change40.67

Avg Trading Volume Last 3 months8.47

Price - 5 Day % Change0.61

Price % Change Month To Date−0.62

Relative (S&P500) price percent change - 04 week4.08

52 week High Date18 Sep 2026

Price - 26 week price percent change25.01

PDATE23 Sep 2026

Price - YTD price percent change38.32

Relative (S&P500) price percent change - 52 week54.34

NPRICE1,962.60

Relative (S&P500) price percent change - 26 week25.75

52 week Low1,251.60

52 week High2,038.00

Beta0.29

Relative (S&P500) price percent change - Year to Date57.53

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year

₹6.00

Dividend yield0.31%
Payout ratio13.34%
5-year average dividend₹4.40 a share
Latest dividend₹6.00 per share · 7 Aug 2026

Corporate calendar

13 Aug 2026MeetingAnnual General Meeting
13 Aug 2026BoardQuarterly Results
7 Aug 2026Dividend₹6.00 per share · 600% · Final dividend
29 May 2026BoardAudited Results & Dividend
13 Feb 2026BoardQuarterly Results
13 Nov 2025BoardQuarterly Results
11 Aug 2025MeetingAnnual General Meeting
11 Aug 2025BoardQuarterly Results

Show 13 older events

29 May 2025BoardAudited Results & Final Dividend
13 Feb 2025BoardQuarterly Results
25 Nov 2024Dividend₹2.00 per share · 200% · Interim dividend
14 Nov 2024BoardQuarterly Results & Interim Dividend
13 Aug 2024MeetingAnnual General Meeting
6 Aug 2024Dividend₹2.00 per share · 200% · Final dividend
30 Mar 2024MeetingPostal Ballot
22 Nov 2023Dividend₹2.00 per share · 200% · Interim dividend
10 Aug 2023MeetingAnnual General Meeting
31 Mar 2023MeetingPostal Ballot
22 Nov 2022Dividend₹4.00 per share · 400% · Interim dividend
10 Jan 2022SplitStock split — face value ₹2 → ₹1
22 Nov 2021Dividend₹8.00 per share · 400% · Interim dividend

About IPCA Laboratories

Biotechnology & Drugs

Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.

Key people

Premchand GodhaExecutive Chairman of the Board
Pranay Premchand GodhaChief Executive Officer, Managing Director, Executive Director
Ajit Kumar JainChief Financial Officer, Managing Director, Executive Director
Pabitra Kumar BhattacharyaPresident - Operations (API)
Sunil GhaiPresident - Marketing
Sanjay U. KapadiaPresident - Corporate Quality Assurance

Company facts

NSE symbolIPCALAB
BSE code524494
ISININE571A01038
IndustryBiotechnology & Drugs
IndexNIFTY 500
Market cap₹50,568 Cr
Revenue (FY26)₹9,646 Cr
Net profit (FY26)₹1,141 Cr

In the News

Recent headlines about IPCA Laboratories — they open on Mint in a new tab.

Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Eight stocks to buy
The Indian stock market is expected to open quietly on September 18, following mixed global cues. The Sensex ended slightly down, while the Nifty 50 was modestly up. Analysts suggest monitoring key resistance and support levels as geopolitical concerns persist.
18 Sep 2026 · 5 min read · Mint ↗
Stock market today: Gift Nifty hints a weak start; five day trading stocks to buy on Thursday, 27 August
The Indian stock market is set to open lower on 27 August, following a negative trend in global markets. The Sensex fell 183.15 points, while the Nifty 50 declined 126.80 points. Investors await clarity from Fed Chair Warsh's speech on interest rates.
27 Aug 2026 · 5 min read · Mint ↗
Welspun Corp leads as over 10 Nifty 500 stocks gain 10–23% this week despite market volatility
Welspun Corp shares surged 23.4%, alongside significant gains for Jyoti CNC Automation and Balrampur Chini Mills. Despite a volatile market influenced by geopolitical tensions and rising oil prices.
23 Aug 2026 · 2 min read · Mint ↗
Top Gainers & Losers on 17 August: NMDC Steel, LG Electronics, BSE, Tata Tech, Infosys, Voltas among top losers
Indian stocks remained subdued on August 17, with the Nifty down 0.11% and the Sensex down 0.19% due to ongoing Middle East conflicts and high crude oil prices. Despite this, midcap and small-cap indices saw slight gains.
17 Aug 2026 · 2 min read · Mint ↗
Q1 results 2026: Tata Motors PV to Brainbees Solutions among companies to declare Q1 results today; full list here
Tata Motors Passenger Vehicles, Max Healthcare Institute, Honasa Consumer, Brainbees Solutions, Ipca Laboratories, Jubilant FoodWorks, LG Electronics India, Awfis Space Solutions are among the companies to report their Q1 results FY27 today.
13 Aug 2026 · 4 min read · Mint ↗
Stock market today: Gift Nifty hints a flat start; eight day trading stocks to buy on Thursday, 6 August
Indian stock markets are expected to open subdued on Aug 6 amid mixed global signals. The Nifty and Sensex saw slight gains earlier, while oil prices fell amid Iran-Oman negotiations. Analysts suggest cautious trading for equities, with significant resistance levels noted for Bank Nifty.
6 Aug 2026 · 5 min read · Mint ↗
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 6 August 2026
Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today — BLS International Services, Usha Martin, 360 One Wam, Netweb Technologies India, and IPCA Laboratories.
6 Aug 2026 · 5 min read · Mint ↗
Stock market today: Gift Nifty hints flat start; US-Iran talks, weak yen to crude oil prices - 8 stocks to buy or sell
The Indian stock market may open quietly on Wednesday, influenced by global market trends. Domestic indices dropped yesterday, with the Nifty 50 and BSE Sensex both closing lower. Oil prices rose slightly amid ongoing geopolitical tensions between the US and Iran.
1 Jul 2026 · 5 min read · Mint ↗

Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →

Frequently Asked Questions

IPCA Laboratories (NSE: IPCALAB) last traded at ₹1,994.70 on the NSE, up 1.56% (₹30.64) on the day, as of 24 Sep 2026, 8:34 AM. On the BSE it was ₹1,993.80. The day's range was ₹1,966.65 – ₹2,005.55.

IPCA Laboratories's 52-week high is ₹2,039.30 (18 Sep 2026) and its 52-week low is ₹1,252.95 (24 Oct 2025). At ₹1,994.70 the share is 2.2% below its high and 59.2% above its low.

IPCA Laboratories's market capitalisation is ₹50,568 Cr (₹50,568 Cr). It is part of the NIFTY 500 index.

IPCA Laboratories's P/E ratio (trailing 12 months) is 32.95. The sector average is 36.50, so investors pay 10% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹51.63.

IPCA Laboratories shares are up 40.67% over the last year, up 38.32% so far this year, up 25.01% over 6 months, up 21.06% over 3 months. Over the last year the stock did 54.34% better than the market.

In FY26 (year to Mar 2026), IPCA Laboratories reported revenue of ₹9,646 Cr (up 7.91% on the year before) and a net profit of ₹1,141 Cr. Earnings per share were ₹44.98.

Yes. IPCA Laboratories's latest dividend is ₹6.00 per share (600%, final dividend), with an ex-date of 7 Aug 2026. The dividend yield is 0.31%. It has paid 6 dividends in the records shown on this page.

Of 16 analysts covering IPCA Laboratories, 12 are bullish (7 strong buy, 5 buy), 2 say hold and 2 are bearish. The consensus is Buy (average rating 2.00 on a scale where 1 is Strong Buy and 5 is Strong Sell). Analyst views are opinions, not a guarantee.

As of Jun 2026: Promoter 44.72%, FII 10.72%, MF 31.15%, Other 13.41%.

IPCA Laboratories's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.

Price returns

Moving averages — price is above 6 of 6

Year by year

Quarter by quarter

Balance sheet — FY26

Cash flow — FY26

Votes

How the votes changed

Valuation Is the price reasonable?

Profitability Of every ₹100 of sales, how much is kept?

Returns & efficiency How well does it use its money?

Growth Is the business getting bigger?

Financial strength Can it pay its bills and debts?

Per share What each share stands for

Valuation

Per share

Margins

Growth

Financial strength

Returns & efficiency

Price & volume

Corporate calendar

Key people

Company facts

Frequently Asked Questions

What is IPCA Laboratories share price today?

What is the 52-week high and low of IPCA Laboratories shares?

What is the market capitalisation of IPCA Laboratories?

What is the P/E ratio of IPCA Laboratories?

How has IPCA Laboratories stock performed?

What were IPCA Laboratories's latest annual results?

Does IPCA Laboratories pay a dividend?

What do analysts recommend for IPCA Laboratories shares?

What is the shareholding pattern of IPCA Laboratories?

Who are IPCA Laboratories's competitors?